Tourmaline Bio’s Post

A single blood test that measures inflammation and fat can predict women's risk for cardiovascular disease 30 years later, a new study published in the New England Journal of Medicine suggests. Testing two types of fat in the bloodstream along with C-reactive protein, a marker of inflammation, may move the cardiology field closer to vital discoveries, researchers said. Participants with the highest levels of LDL cholesterol incurred a 36% higher associated risk for heart disease compared to women with the lowest levels. Individuals with the most significant levels of Lp(a) had a 33% elevated associated risk, and those with the greatest levels of CRP had a 70% heightened associated risk. When researchers assessed all three measures, participants with the highest levels had more than a 1.5 times increased associated risk for stroke and more than a three times raised associated risk for coronary heart disease compared to women with the lowest levels. "Based on a single blood sample, we could predict not just five- or 10-year risk of future heart attack, stroke and cardiovascular death, but we could predict risks a full 30 years in advance," said the study's lead author, Dr. Paul Ridker. #heart #stroke https://ow.ly/VlWN50ThXfu

🔬 Exciting Discovery in Cardiovascular Health for Type 2 Diabetes! 🩸 Researchers unveil a potential breakthrough in treating an underlying cause of cardiovascular disease in individuals with Type 2 diabetes. 👥 Over 30 million Americans grapple with Type 2 diabetes, facing a heightened risk of cardiovascular complications due to endothelial cell damage, resulting in blood vessel hardening. Identifying novel therapeutic targets is crucial to enhancing endothelial function and combating cardiovascular risks.🔍 🌐 Dive deeper into the groundbreaking research: https://shorturl.at/exUW5 #Type2Diabetes #CardiovascularHealth #MedicalResearch #HealthInnovation#NextGenPrecisionHealth #ResearchDiscovery #ReadMore #HealthScience 🚀

📢 Exploring the Protective Role of Lactoferrin in Atherosclerosis Cardiovascular diseases, including stroke, hypertension and heart failure, have a significant impact on global health and are often due to atherosclerosis. This disease, characterized by endothelial cell dysfunction, smooth muscle proliferation, cholesterol accumulation and chronic inflammation, leads to serious complications such as heart attacks. At Mercurius Production, we are committed to advancing the understanding and benefits of lactoferrin (Lf) in combating atherosclerosis and promoting cardiovascular health. 🔍 Key Points on Lactoferrin's Potential Role: 1.⁠ ⁠Correlation with Atherosclerosis Risk: o Endogenous Lf levels correlate with the severity of coronary stenosis and cardiovascular events. o Higher Lf levels are observed in patients with significant coronary stenosis and ischemic heart disease. 2.⁠ ⁠Improving Cholesterol Metabolism: o Bovine Lf (bLf) can increase HDL levels while reducing "bad cholesterol" (triacylglycerides, non-esterified fatty acids). o bLf promotes bile acid excretion, lowering liver cholesterol and alleviating atherosclerosis symptoms. 3.⁠ ⁠Inhibiting Foam Cell Formation: o bLf may neutralize modified LDL's negative charge, inhibiting macrophage binding and reducing foam cell formation. 4.⁠ ⁠Binding to Advanced Glycation End Products (AGEs): o Lf can bind to AGEs, potentially impacting oxidative stress and atherosclerotic disease pathogenesis. 5.⁠ ⁠Reducing Homocysteine and Leptin Levels: o bLf intake significantly lowers these markers, crucial in preventing cardiovascular disease. 6.⁠ ⁠Anti-inflammatory and Antioxidant Properties: o Lf inhibits excessive inflammatory responses and oxidative stress, critical factors in atherosclerosis development. These promising findings underscore Lactoferrin's potential as a preventive and therapeutic agent in atherosclerosis management. We look forward to continuing our research and contributing to innovative healthcare solutions. 🌐 Learn more on our website: https://lnkd.in/ejqMUkwg #lactoferrin #health #protein #atherosclerosis #germany #europe

8 reasons why Lp(a) levels should be measured in everyone at least once in a lifetime: 1. To provide answers to patients who develop cardiovascular diseases #CVD despite having zero or few conventional risk factors. 2. To identify individuals who may benefit from earlier and more intense management of conventional CVD risk factors 3. To identify individuals at very high genetic risk of Atherosclerotic Cardiovascular Disease #ASCVD. 4. To prevent cardiovascular events (ie. heart attack) in families at high genetic risk of ASCVD. 5. Measuring Lp(a) levels is a low-cost way of identifying individuals at high risk of ASCVD. 6. Contemporary assays do identify individuals with high Lp(a) levels. 7. To improve Lp(a) and ASCVD prevention research. 8. To ensure timely implementation of new treatments targeting high Lp(a) to prevent ASCVD. A medical perspective in the new publication by Benoit Arsenault and Pia R. Kamstrup in the European Heart Journal. #healthliteracy #patientengagement #informedconsent #citizenengagement #personalisedmedicine https://lnkd.in/ef9NKSyd

Global trends in cardiovascular disease (CVD) Learn more about updated trends CVD burden globally as discussed by Chadi Alraies, MD FACC FSCAI #cardiologyupdate #CVD #cardiovasculardisease

Entering the New Year, a glance at cardiovascular disease prevention progress sparks hope. The transformation in preventive cardiology, driven by conquering cholesterol through genetic insights and clinical trials, showcases the synergy between industry and academia. The collaborative efforts behind statins, ezetimibe, PCSK9 inhibitors, and bempedoic acid underscore achievements. While lifestyle fundamentals persist, these therapies have notably targeted LDL cholesterol. Yet, challenges endure, urging exploration of residual risks. Beyond lipids, inflammation's role prompts the exploration of anti-inflammatory strategies. Notably, bempedoic acid's ATP citrate lyase inhibition hints at broader metabolic benefits. Moving forward, the emphasis is on ensuring fair access and efficient implementation of proven therapies, guided by robust clinical trials. The cholesterol conquest lessons chart a course for ongoing strides in cardiovascular disease prevention. https://lnkd.in/edENdDjF

Checking hsCRP, LDL and lp(a) in women at ~55yo can predict 30-year CV outcomes. While each was independently predictive of risk, the three combined together gave the best prediction. We probably don’t check hsCRP enough especially now that we have CV indications for colchicine

Lipoprotein(a) is a historically overlooked genetic risk factor associated with cardiovascular health. High levels of Lp(a) may significantly increase a person’s risk of heart disease, but most people don't know their lipoprotein(a) levels. Amgen is committed to addressing unmet needs in cardiovascular disease, including risk factors like Lp(a). This week, the National Lipid Association shared updated guidance that state there is now sufficient evidence to support the recommendation that every adult have their Lp(a) measured at least once in their lifetime. 🔗 8 things to know about Lp(a): https://amgen.ly/3VI2wP4

🩺 Revolutionary Advancements in Cardiovascular Health 🩺 A groundbreaking study has shown that a single blood test in midlife can predict 30-year cardiovascular disease risks for women. By measuring inflammation and lipids, healthcare providers can detect and treat heart disease much earlier than ever before. As Dr. Paul M. Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, Boston, emphasized, “We can’t treat what we don’t measure, and we hope these findings move the field closer to identifying even earlier ways to detect and prevent heart disease.” This research could be a game-changer in the fight against cardiovascular disease, offering new hope for prevention and improved outcomes. #CardiovascularHealth #WomensHealth #Innovation #PreventiveMedicine #HealthcareTransformation Kaleidoscope Innovation Infosys Infosys Life Sciences Infosys Healthcare https://lnkd.in/gpC6RGRF

We need to start early and hit hard! That is the message that is increasingly coming out of scientific studies about atherosclerosis (often termed “hardening of the arteries”), the name given to the degeneration of the arteries in the body which gives rise to plaques which in turn gives rise to various cardiovascular diseases such as heart attacks and strokes. A recently published paper from a very respected group in cardiovascular research adds further weight to this thinking ( https://lnkd.in/gE-v-Ciu ). Over 3,000 people aged between 40 – 55 years of age at the start of the study were examined for evidence of atherosclerosis. Even at this young age (from my perspective!) about 44% had silent atherosclerosis, that is to say it had not yet caused a clinical problem like a heart attack but it was lurking waiting. Over the 6 years of the study, as people got older it often got worse and more people developed it. Having high blood pressure, smoking and having higher LDL cholesterol levels were important risk factors that predicted this progression. However, if tightly controlled at an earlier age it was possible to slow down the disease process and if people stopped smoking and their LDL cholesterol was significantly reduced there was a greater chance of the disease not just slowing down but reversing, and this was more likely to occur if the person was younger when they started intervening. So, what is the message? If you are over 40 talk to your local doctor about ways to find out whether you have silent atherosclerosis. There are a few ways to do this including a coronary artery calcium score (a simple painless CT scan using no dye and low dose radiation) and assess your risk factors knowing what is already going on inside your body and then take action early to give yourself the best chance of not meeting the biggest killer in the world, atherosclerotic cardiovascular disease, as you are walking down the street one day. Advara HeartCare